Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Cullinan Therapeutics Inc

CGEM ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: STRONG BUY

Last Close

$20.34

▲ +3.56%

Market Cap $1.31B · Vol 215.37K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.31B

Small Cap

Div Yield

N/A

EPS Growth

+5.41%

YoY

RSI (14)

72.49

Momentum

Beta

0.03

vs Market

52W High

$20.97

3.00% below

52W Low

$5.68

258.10% above

Volume

215.37K

Avg 224.93K

P/B

1.53

Price-to-book

ROE

-44.02%

Return on equity

Free Float

98.35%

Public shares

Shariah Compliance8 STANDARDS

✗ Cullinan Therapeutics Inc (CGEM) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CGEM pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+14.72%

+14.46%

+25.94%

+75.50%

YTD

+96.52%

+168.34%

+99.22%

-26.60%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-219,879,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-44.02%
ROA · ROIC	-41.09% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.53
P/FCF	N/A
EPS Growth	+5.41%
Outstanding Shares	64.35M

Technical Indicators

50-Day SMA	$16.95
200-Day SMA	$13.57
RSI (14)	72.49
Beta	0.03
52-Week High	$20.97
52-Week Low	$5.68

Volume Today	215.37K
Avg Daily Volume (30D)	224.93K
Relative Volume	0.96x
Volatility (10D)	48.86
Volatility (30D)	52.94
Free Float	98.35%

Analyst Consensus

STRONG BUY

Current Price $20.34

Mean Target $36.91

52W Low$5.68 52W High$20.97

Current

Target

$5.68 $20.97

Current Analyst target

+81.46% upside potential · 13 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00HW2DGR3

ISINUS2300311063

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.